Advertisement
AGEN vs AMRN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and AMRN is a Hold.
AGEN's Stochastic Oscillator driving into overbought zone
The Stochastic Oscillator for AGEN moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
AGEN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Indicator exited the oversold zone, 30 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AGEN as a result. In 64 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AGEN just turned positive on October 29, 2026. Looking at past instances where AGEN's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 64 of 94 cases where AGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.622) is normal, around the industry mean (3.498). P/E Ratio (2.383) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AMRN's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 183 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 78 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.553) is normal, around the industry mean (-1.421). P/E Ratio (-9.675) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
AGEN | AMRN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 92 | |
PRICE GROWTH RATING 1..100 | 37 | 71 | |
P/E GROWTH RATING 1..100 | 12 | 27 | |
SEASONALITY SCORE 1..100 | 49 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AGEN's Valuation (54) in the Biotechnology industry is in the same range as AMRN (63) in the Pharmaceuticals Other industry. This means that AGEN’s stock grew similarly to AMRN’s over the last 12 months.
AGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that AGEN’s stock grew similarly to AMRN’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as AGEN (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to AGEN’s over the last 12 months.
AGEN's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for AMRN (71) in the Pharmaceuticals Other industry. This means that AGEN’s stock grew somewhat faster than AMRN’s over the last 12 months.
AGEN's P/E Growth Rating (12) in the Biotechnology industry is in the same range as AMRN (27) in the Pharmaceuticals Other industry. This means that AGEN’s stock grew similarly to AMRN’s over the last 12 months.
| AGEN | AMRN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Advances ODDS (%) | 8 days ago 84% | 2 days ago 74% |
| Declines ODDS (%) | 10 days ago 90% | 13 days ago 85% |
| BollingerBands ODDS (%) | N/A | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGEN’s FA Score shows that 1 FA rating(s) are green while AMRN’s FA Score has 1 green FA rating(s).
- AGEN’s FA Score: 1 green, 4 red.
- AMRN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGEN’s TA Score shows that 5 TA indicator(s) are bullish while AMRN’s TA Score has 4 bullish TA indicator(s).
- AGEN’s TA Score: 5 bullish, 4 bearish.
- AMRN’s TA Score: 4 bullish, 4 bearish.
Price Growth
AGEN (@Biotechnology) experienced а +5.25% price change this week, while AMRN (@Pharmaceuticals: Major) price change was -2.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.36%. For the same industry, the average monthly price growth was +2.43%, and the average quarterly price growth was +7.01%.
Reported Earning Dates
AGEN is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AGEN has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To AGEN | 1D Price Change % | ||
|---|---|---|---|---|
| AGEN | 100% | -1.82% | ||
| TAOX - AGEN | 91% Closely correlated | -5.15% | ||
| PALI - AGEN | 81% Closely correlated | -5.04% | ||
| AXON - AGEN | 42% Loosely correlated | -0.21% | ||
| AMRN - AGEN | 37% Loosely correlated | +0.09% | ||
| QTTB - AGEN | 36% Loosely correlated | -0.11% | ||
More | ||||
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +0.09% | ||
| CNTB - AMRN | 55% Loosely correlated | -9.08% | ||
| HRTX - AMRN | 44% Loosely correlated | +0.94% | ||
| MGNX - AMRN | 44% Loosely correlated | +3.42% | ||
| ALXO - AMRN | 43% Loosely correlated | -13.62% | ||
| ARWR - AMRN | 40% Loosely correlated | -0.49% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CLOC | 24.95 | 0.01 | +0.02% |
| AAM Crescent CLO ETF (CLOC) | |||
| QDTE | 26.31 | -0.10 | -0.38% |
| Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF (QDTE) | |||
| FCAL | 48.03 | -0.26 | -0.54% |
| First Trust California Municipal High Income ETF (FCAL) | |||
| AVEM | 85.11 | -0.60 | -0.70% |
| Avantis Emerging Markets Equity ETF (AVEM) | |||
| TYLG | 38.56 | -0.43 | -1.11% |
| Global X Information Technology Covered Call & Growth ETF (TYLG) | |||